Clinical trials: Breakthrough Cancer Pain
Cancer, Pain
Sublingual Methadone for the Management of Cancer-related Procedure Pain in Inpatients
The purpose of this Phase II study is to determine the feasibility of the dose titration and assessment protocol in the impatient population, in the clinical setting of preventing or managing breakthrough pain, before conducting…
- Trial name
- NCT00351637
- Testing
- Sublingual Methadone
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- Alberta Health services
Cancer
The Cancer Pain and Unmet Needs Study
The aim of the following study is to identify if cancer patients in pain report unmet supportive care needs that are comparable to the general cancer population or if these unmet needs are exacerbated depending on whether their…
- Trial name
- NCT01651910
- Where
- United Kingdom
- Volunteers
- 162 people
- Sponsor
- University of Surrey
Pain, Unspecified Adult Solid Tumor, Protocol Specific
Inhaled Morphine Compared With Morphine By Mouth in Treating Cancer Patients With Breakthrough Pain
RATIONALE: Morphine that is inhaled may be more rapidly absorbed than morphine that is given by mouth. It is not yet known if inhaled morphine is more effective than morphine given by mouth in relieving breakthrough pain.
- Trial name
- NCT00020618
- Testing
- morphine sulfate, quality-of-life assessment
- Where
- United States
- Sponsor
- Dana-Farber Cancer Institute
Pain, Cancer
A Phase III Clinical Study of KW-2246
This study is designed to assess the safety and efficacy of long-term KW-2246 treatment as rescue medication for breakthrough pain.
- Trial name
- NCT00683995
- Testing
- KW-2246 (fentanyl citrate)
- Where
- 20 sites in Japan
- Volunteers
- 43 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Cancer: Breakthrough Pain, Cancer: Extreme Pain on Movement
Comparison of Oral Morphine Versus Nasal Ketamine Spray With Chitosan in Cancer Pain Outpatients
34 adult (>18 years) cancer pain outpatients with Opioid base therapy because of pain and breakthrough pain or extreme pain on movement will be included in this prospective, randomized, double-blind crossover study.
- Trial name
- ONKEMI (NCT02591017)
- Testing
- Morphine, Ketamine, Chitosan
- Where
- Switzerland
- Volunteers
- 11 people
- Sponsor
- University Hospital, Basel, Switzerland
Swallowing-induced Pain
Doxepin Solution for Alleviation of Stubborn Breakthrough Pain Induced by Swallowing in Patients Receiving Radiotherapy for Nasopharyngeal Carcinoma
The goal of this clinical trial is to explore the effectiveness and adverse reactions of doxepin solution spray for alleviation of stubborn breakthrough pain induced by swallowing in patients receiving radiotherapy for…
- Trial name
- NCT06017895
- Testing
- doxepin solution
- Where
- China
- Volunteers
- 178 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Breakthrough Pain, Pain Due to Certain Specified Procedures
Procedural Pain in Palliative Care: Prevalence, Intensity and Treatment
This study aims to assess self reported procedural pain compared with background pain and evaluate pain intensity differences across six standard procedures.
- Conditions
- Breakthrough Pain, Pain Due to Certain Specified Procedures, Pain, Cancer
- Trial name
- NCT02437929
- Testing
- Mobilization, Positioning, Personal Hygiene Care
- Where
- Italy
- Volunteers
- 1,079 people
- Sponsor
- Antea Foundation
Gastrostomy, Breakthrough Pain
Analgesic Efficacy of Transmucosal Fentanyl for Breakthrough Pain Caused by Interventional Gastrostomy
Patients with Head \& Neck Squamous Cell Carcinoma often need a gastrostomy. It can be performed with a radiological approach. This procedure is usually not performed under general anesthesia, but local anesthesia is not…
- Conditions
- Gastrostomy, Breakthrough Pain, Upper Aerodigestive Tract Neoplasms
- Trial name
- ANTALGIP (NCT02869321)
- Testing
- Fentanyl, Morphine Sulfate, Gastrostomy
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Central Hospital, Nancy, France
Breakthrough Pain
Quality of Life Study in Patients With Cancer Breakthrough Pain Treated in Palliative Care Units
Patients treated in Palliative Care Units are potentially fragile patients, especially in our case, which are cancer patients. The management of these patients is usually done from experience, because these patients rarely meet…
- Trial name
- CAVIDIOPAL (NCT02840500)
- Testing
- No intervention
- Where
- 10 sites in Spain
- Volunteers
- 101 people
- Sponsor
- Angelini Farmacéutica
Radiation-induced Oropharyngeal Mucositis, Swallowing-induced Breakthrough Pain
A Real-world Observational Study of a Mucosal Contouring Method for Radiation-induced Oropharyngeal Mucositis
The performance of the predictive models for the occurrence and severity of oropharyngeal mucositis established using either oral cavity contouring method or mucosa surface contouring method was unsatisfactory in nasopharyngeal…
- Trial name
- NCT06308328
- Where
- 10 sites in China
- Volunteers
- 718 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Cancers, Pain
Long Term Safety Study of Nasalfent (Fentanyl Citrate Nasal Spray) for Treatment of Breakthrough Cancer Pain
Cancer patients taking regular medication for their pain often still have episodes of severe pain that 'break through' despite their background pain treatment.
- Trial name
- NCT00458510
- Testing
- Fentanyl (Nasalfent, Fentanyl Citrate Nasal Spray)
- Volunteers
- 403 people
- Sponsor
- Archimedes Development Ltd
Neoplasm Metastases
Oral Piroxicam Versus Buccal Fentanyl in Breakthrough Pain
100 patients with Breakthrough pain will be allocated to receive either oral prioxicam (OP) (n=50) or sublingual fentanyl (SLF) (n=50) .
- Trial name
- NCT02382653
- Testing
- oral perixicam
- Volunteers
- 100 people
- Sponsor
- Tanta University
Breakthrough Cancer Pain
Safety of Fentanyl TAIFUN Treatment
A Multicenter, Multinational, Randomized, Open-Label, Parallel-Group Trial to Evaluate hte Safety of Fentanyl TAIFUN Treatment after titrated Dose Administration and the Current Breakthrough Pain Treatment for Breakthrough Pain…
- Trial name
- FINDS (NCT00822614)
- Testing
- Fentanyl TAIFUN, Opioid
- Where
- Poland
- Volunteers
- 500 people
- Sponsor
- Akela Pharma, Inc.
Breakthrough Cancer Pain
Observational Study of Efficacy, Safety and Tolerability of Fentanyl in Korean Cancer Patients
The purpose of this observational study is: To observe the efficacy, safety, and tolerability of Abstral ODT for the alleviation of breakthrough cancer pain in Korean patients with various cancers in real-world clinical settings…
- Trial name
- OASIS (NCT03895762)
- Testing
- Abstral Oral Disintegrating Tablet (ODT)
- Where
- South Korea
- Volunteers
- 143 people
- Sponsor
- A.Menarini Asia-Pacific Holdings Pte Ltd
Pain, Breakthrough Cancer Pain
A Clinical Trial to Assess the Clinical Benefit of SSR411298 as Adjunctive Treatment for Persistent Cancer Pain
The primary objective of this study is to evaluate the efficacy of SSR411298 200 mg daily compared to placebo as adjunctive treatment for persistent cancer pain based on Numeric Rating Scale (NRS).
- Trial name
- ACT11705 (NCT01439919)
- Testing
- SSR411298
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Sanofi
Pain
Conversion From Fast Acting Oral Opioids to Abstral®
The purpose of this study is to evaluate safety and efficacy when using a novel dose conversion strategy to switch from immediate release oral opioids to sublingual (SL) fentanyl (Abstral) for treatment of breakthrough cancer…
- Trial name
- NCT01315886
- Testing
- SL fentanyl
- Where
- Sweden
- Volunteers
- 8 people
- Sponsor
- Orexo AB
Breakthrough Pain, Cancer
Efficacy and Safety of Fentanyl ETHYPHARM for Breakthrough Pain in Opioid-treated Patients With Cancer
The purpose of the study is to assess the clinical effectiveness of Fentanyl ETHYPHARM when used to relieve breakthrough pain (BTP) in opioid-treated cancer patients.
- Trial name
- ETHYFYL (NCT01842893)
- Testing
- Fentanyl Ethypharm
- Where
- Czechia
- Volunteers
- 91 people
- Sponsor
- Ethypharm
Breakthrough Cancer Pain
Characterisation and Epidemiology of Breakthrough Cancer Pain in Spain
The purpose of this study is to determine the prevalence of breakthrough cancer pain and characterize breakthrough cancer pain in an unselected, representative cohort of cancer outpatients with or without pain who attend…
- Trial name
- NCT02899884
- Testing
- No Intervention
- Where
- 36 sites in Spain
- Volunteers
- 3,765 people
- Sponsor
- Takeda
Breakthrough Cancer Pain
Effectiveness and Tolerance of Inhaled Fentanyl Aerosol (25µg/Dose) in Chinese Patients With BTcP
Breakthrough cancer pain (BTcP) is a common problem in patients with cancer. This is a phase IIa dose-response and safety study of inhaled fentanyl aerosol (25µg/dose) in Chinese patients with breakthrough cancer pain.
- Trial name
- NCT05531422
- Testing
- Inhaled fentanyl aerosol
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Lee's Pharmaceutical Limited
Pain, Cancer
OraVescent Fentanyl (OVF) for the Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients
The purpose of this study is to evaluate the long-term safety and efficacy of OraVescent fentanyl to treat breakthrough pain episodes in cancer patients who are already opioid tolerant.
- Trial name
- NCT00105937
- Testing
- OraVescent fentanyl citrate
- Where
- 43 sites in United States
- Volunteers
- 300 people
- Sponsor
- Cephalon